Post-earnings recap
Reported
Tue, Jul 31, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a smaller-than-expected loss per share, which was a positive surprise for investors. However, the stock still fell by 1.81%, likely due to the lack of revenue data and forward guidance. Investors may be concerned about the company's current financial position and future outlook without clear guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | +58.33% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism regarding future projects. They emphasized their commitment to innovation and growth.
Management highlighted ongoing efforts in research and development.
They expressed confidence in their pipeline despite current losses.